Equities

BSF Enterprise PLC

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BSFA:LSE

BSF Enterprise PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.80
  • Today's Change-0.20 / -10.00%
  • Shares traded299.15k
  • 1 Year change-34.55%
  • Beta3.1175
Data delayed at least 20 minutes, as of Feb 10 2026 14:35 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

BSF Enterprise PLC is a United Kingdom-based biotech company. The Company develops and commercializes cell-based tissue engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. The principal activity of the Company is to undertake the acquisition of businesses in the biotechnology, marketing and e-commerce sectors. The Company operates through its wholly owned subsidiaries, 3D Bio-Tissues Limited (3DBT), Lab Grown Leather Limited (LGL), Kerato Limited (Kerato), and BSF Enterprise (Hong Kong) Limited (BSF HK). 3DBT is a tissue engineering company developing processes and tools for others to create functional tissues from a range of cell types. This includes a platform for generating structured tissues as well as media supplements that can accelerate and increase cell performance. Kerato utilizes multi-patented technology with expertise in tissue engineering and biomaterials to develop bio-equivalent corneal tissue.

  • Revenue in GBP (TTM)52.84k
  • Net income in GBP-1.11m
  • Incorporated2018
  • Employees10.00
  • Location
    BSF Enterprise PLCGround Floor, 31 Old Burlington StreetLONDON W1S 3ASUnited KingdomGBR
  • Phone+44 203 283 4590
  • Websitehttps://bsfenterprise.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kanabo Group PLC1.14m-8.18m1.42m17.00--0.2402--1.25-0.013-0.0130.00180.00940.105416.2843.8567,058.82-75.70-75.83-81.16-83.337.89---718.33-1,267.352.72-63.430.0337--48.42---16.26------
BSF Enterprise PLC52.84k-1.11m2.57m10.00--0.9447--48.59-0.0093-0.00930.00040.02120.01630.94964.075,284.00-34.25-35.35-37.51-38.06-34.37---2,107.34-4,267.991.38-710.580.00---8.61--33.41------
Nuformix PLC0.00-652.59k4.64m3.00--5.92-----0.0004-0.00040.000.00040.00-------65.61---88.76----------------------82.08------
CRISM' Therapeutics Corp25.00k-1.49m7.24m0.00--4.20--289.72-0.0458-0.04690.00080.03330.012--0.0305---71.61-9.33-88.05-9.6872.00---5,952.00-32,053.62----0.00------69.17---41.03--
Oxford Biodynamics PLC1.10m-11.15m12.23m44.00--5.00--11.17-0.0096-0.00960.00080.00060.10852.221.21---110.46-70.62-148.46-89.0347.67---1,018.54-1,715.570.8005-30.880.8208--72.1719.153.58---11.79--
Probiotix Health PLC2.22m-736.00k12.26m4.00--6.85--5.52-0.005-0.0050.01460.01131.0518.573.01555,250.00-34.67-21.03-46.17-27.3053.1754.10-33.14-26.583.99--0.00--12.5536.47-13.39---41.50--
Data as of Feb 10 2026. Currency figures normalised to BSF Enterprise PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.